Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vemurafenib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF known ✓ | P15056 | 3/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 2/20 | 1.00 |
| ▸ | RAF1 | P04049 | 2/20 | 1.00 |
| ▸ | KDR | P35968 | 2/20 | 1.00 |
| ▸ | MAP2K2 | P36507 | 2/20 | 1.00 |
| ▸ | TGFBR2 | P37173 | 2/20 | 1.00 |
| ▸ | NEK2 | P51955 | 2/20 | 1.00 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 1.00 |
| ▸ | TNK2 | Q07912 | 2/20 | 1.00 |
| ▸ | MAP2K5 | Q13163 | 2/20 | 1.00 |
| ▸ | PTK6 | Q13882 | 2/20 | 1.00 |
| ▸ | NEK11 | Q8NG66 | 2/20 | 1.00 |
| ▸ | MAP3K20 | Q9NYL2 | 2/20 | 1.00 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | KRAS | P01116 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | RET | P07949 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12891936 | 1.00 | BRAF (1.00) | BRAFRIPK2RAF1KDRMAP2K2 | |
| Vemurafenib SCHEMBL298931 | 1.00 | BRAF (1.00) | BRAFRIPK2RAF1KDRMAP2K2 | |
| Vemurafenib SCHEMBL29356185 | 1.00 | BRAF (1.00) | BRAFRIPK2RAF1KDRMAP2K2 | |
| Vemurafenib SCHEMBL17784481 | 0.95 | BRAF (0.91) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL298368 | 0.95 | BRAF (0.91) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL19575141 | 0.94 | BRAF (0.89) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL298927 | 0.94 | BRAF (0.89) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL7876722 | 0.94 | BRAF (0.89) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL20408711 | 0.94 | BRAF (0.88) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL293053 | 0.93 | CYP2C19 (1.00) | BRAFRIPK2RAF1KDRMAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12354130-B2 | Combination therapies | GENENTECH, INC. (US) | 2025-07-08 | — | — | US | claimed |
| EP-4272735-B1 | IMMEDIATE-RELEASE TABLETS CONTAINING A DRUG AND PROCESSES FOR FORMING THE TABLETS | GENENTECH INC (US) | 2025-06-18 | — | — | EP | claimed |
| CN-114177157-B | Immediate release tablet containing a drug and method for forming a tablet | 基因泰克公司 | 2024-08-02 | — | — | CN | claimed |
| US-20240115555-A1 | METHODS OF TREATING CANCER USING B-RAF INHIBITORS AND IMMUNE CHECKPOINT INHIBITORS | GENENTECH, INC. (US) | 2024-04-11 | — | — | US | claimed |
| US-20240046303-A1 | COMBINATION THERAPIES | GENENTECH INC (US) | 2024-02-08 | — | — | US | claimed |
| EP-4272735-A1 | IMMEDIATE-RELEASE TABLETS CONTAINING A DRUG AND PROCESSES FOR FORMING THE TABLETS | GENENTECH, INC. (US) | 2023-11-08 | — | — | EP | claimed |
| EP-3881833-B1 | IMMEDIATE-RELEASE TABLETS CONTAINING A DRUG AND PROCESSES FOR FORMING THE TABLETS | GENENTECH INC (US) | 2023-11-01 | — | — | EP | claimed |
| US-11783366-B2 | Combination therapies | GENENTECH, INC. (US) | 2023-10-10 | — | — | US | claimed |
| US-20220172244-A1 | COMBINATION THERAPIES | GENENTECH INC (US) | 2022-06-02 | — | — | US | claimed |
| CN-114177157-A | Immediate release tablet containing drug and method for forming tablet | 基因泰克公司 | 2022-03-15 | — | — | CN | claimed |
| EP-4735452-A2 | HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS PROTEIN | Merck Patent GmbH (DE) | 2026-05-06 | — | — | EP | disclosed |
| EP-4735438-A2 | HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS | Merck Patent GmbH (DE) | 2026-05-06 | — | — | EP | disclosed |
| WO-2026090174-A1 | COMPOSITIONS FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS AND METHODS FOR THE SYNTHESIS AND USE THEREOF | BRYET US, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-4731199-A2 | COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING COLORECTAL CANCER | Burzynski, Stanislaw R. (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4731793-A2 | COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING PANCREATIC CANCER | Burzynski, Stanislaw R. (US) | 2026-04-29 | — | — | EP | disclosed |
| WO-2022035997-A1 | IN VIVO ASSEMBLY OF ASGPR BINDING THERAPEUTICS | AVILAR THERAPEUTICS, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
| WO-2022032132-A1 | ADVANTAGEOUS THERAPIES FOR DISORDERS MEDIATED BY IKAROS OR AIOLOS | C4 THERAPEUTICS, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
| WO-2022032026-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | C4 THERAPEUTICS, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
| EP-3941462-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| CN-113968803-A | Novel method for synthesizing 2, 6-difluoro-3-propyl sulfonamide benzoic acid | 苏州匠化生物科技有限公司 | 2022-01-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240046303-A1 | COMBINATION THERAPIES | HGF, MET, FGFR3 | BRAF 124/4885RIPK2 2518/4885RAF1 693/4885 |
| US-11783366-B2 | Combination therapies | HGF, MET, FGFR3 | BRAF 124/4885RIPK2 2518/4885RAF1 693/4885 |
| US-12354130-B2 | Combination therapies | HGF, MET, FGFR3 | BRAF 124/4885RIPK2 2518/4885RAF1 693/4885 |
| US-20220172244-A1 | COMBINATION THERAPIES | HGF, MET, FGFR3 | BRAF 124/4885RIPK2 2518/4885RAF1 693/4885 |
| US-20240115555-A1 | METHODS OF TREATING CANCER USING B-RAF INHIBITORS AND IMMUNE CHECKPOINT INHIBITORS | BRAF, RAF1, NRAS | BRAF 1/4885RIPK2 838/4885RAF1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.